- Home
- GDL vs ATHA Comparison
GDL vs ATHA Comparison
Compare GDL & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ATHA
- Stock Information
- Founded
- GDL 2006
- ATHA 2011
- Country
- GDL United States
- ATHA United States
- Employees
- GDL N/A
- ATHA N/A
- Industry
- GDL Investment Managers
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- GDL Finance
- ATHA Health Care
- Exchange
- GDL Nasdaq
- ATHA Nasdaq
- Market Cap
- GDL 95.2M
- ATHA 93.5M
- IPO Year
- GDL N/A
- ATHA 2020
- Fundamental
- Price
- GDL $8.09
- ATHA $0.67
- Analyst Decision
- GDL
- ATHA Buy
- Analyst Count
- GDL 0
- ATHA 4
- Target Price
- GDL N/A
- ATHA $11.25
- AVG Volume (30 Days)
- GDL 11.2K
- ATHA 14.2M
- Earning Date
- GDL 01-01-0001
- ATHA 11-07-2024
- Dividend Yield
- GDL 6.02%
- ATHA N/A
- EPS Growth
- GDL N/A
- ATHA N/A
- EPS
- GDL N/A
- ATHA N/A
- Revenue
- GDL N/A
- ATHA N/A
- Revenue This Year
- GDL N/A
- ATHA N/A
- Revenue Next Year
- GDL N/A
- ATHA N/A
- P/E Ratio
- GDL N/A
- ATHA N/A
- Revenue Growth
- GDL N/A
- ATHA N/A
- 52 Week Low
- GDL $7.65
- ATHA $0.41
- 52 Week High
- GDL $8.13
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- GDL 41.91
- ATHA 51.78
- Support Level
- GDL $8.09
- ATHA $0.60
- Resistance Level
- GDL $8.21
- ATHA $0.83
- Average True Range (ATR)
- GDL 0.05
- ATHA 0.10
- MACD
- GDL -0.01
- ATHA 0.03
- Stochastic Oscillator
- GDL 0.00
- ATHA 61.60
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.